Multidisciplinary treatment with immune checkpoint inhibitors for advanced stage hepatocellular carcinoma

• Main Authors: Ahlim Lee (Author), Jaejun Lee (Author), Hyun Yang (Author), Soo-Yoon Sung (Author), Chang Ho Jeon (Author), Su Ho Kim (Author), Moon Hyung Choi (Author), Young Joon Lee (Author), Ho Jong Chun (Author), Si Hyun Bae (Author)
• Format: Book
• Published: Korean Liver Cancer Association, 2022-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Hepatocellular carcinoma (HCC) is a cytotoxic chemotherapy-resistant tumor and most HCCs arise in a background of liver cirrhosis of various causes. Although the IMBrave150 trial showed remarkable advancements in the treatment of unresectable HCC with atezolizumab plus bevacizumab (AteBeva), therape...